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Abstract
Background Bioﬁlm formation on indwelling medical
devices is a ubiquitous problem causing considerable
patient morbidity and mortality. In orthopaedic surgery,
this problem is exacerbated by the large number and
variety of material types that are implanted. Metallic
hardware in conjunction with polymethylmethacrylate
(PMMA) bone cement is commonly used.
Questions/purposes We asked whether polymerizable
derivatives of vancomycin might be useful to (1) surface
modify Ti-6Al-4V alloy and to surface/bulk modify
PMMA bone cement to prevent Staphylococcus epide-
rmidis bioﬁlm formation and (2) whether the process
altered the compressive modulus, yield strength, resilience,
and/or fracture strength of cement copolymers.
Methods A Ti-6Al-4V alloy was silanized with methacry-
loxypropyltrimethoxysilane in preparation for subsequent
polymer attachment. Surfaces were then coated with poly-
mers formed from PEG(375)-acrylate or a vancomycin-
PEG(3400)-PEG(375)-acrylate copolymer. PMMA was
loaded with various species, including vancomycin and
several polymerizable vancomycin derivatives. To assess
antibioﬁlm properties of these materials, initial bacterial
adherence to coated Ti-6Al-4V was determined by scanning
electron microscopy (SEM). Bioﬁlm dry mass was deter-
mined on PMMA coupons; the compressive mechanical
properties were also determined.
Results SEM showed the vancomycin-PEG(3400)-
acrylate-type surface reduced adherent bacteria numbers by
approximately fourfold when compared with PEG(375)-
acrylate alone. Vancomycin-loading reduced all mechanical
properties tested; in contrast, loading a vancomycin-acryl-
amide derivative restored these deﬁcits but demonstrated
no antibioﬁlm properties. A polymerizable, PEGylated
vancomycin derivative reduced bioﬁlm attachment but
resulted in inferior cement mechanical properties.
Clinical Relevance The approaches presented here may
offer new strategies for developing bioﬁlm-resistant
orthopaedic materials. Speciﬁcally, polymerizable deriva-
tives of traditional antibiotics may allow for direct
polymerization into existing materials such as PMMA bone
cement while minimizing mechanical property compro-
mise. Questions remain regarding ideal monomer
structure(s) that confer biologic and mechanical beneﬁts.
Introduction
Bioﬁlms have been referred to as the ‘‘hallmark charac-
teristic of periprosthetic joint infection’’ [8]. One report
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ening may actually be the result of undetected bioﬁlms
[45]. The antibiotic concentration required for bactericidal
activity against sessile organisms can be several orders of
magnitude higher than for planktonic bacteria [20], the rule
of thumb being 1000 to 1500 times higher [14]. This places
a premium on extensive wound irrigation and de ´bridement
at the time of surgery followed by lengthy antibiotic
therapy.
A classic strategy used in orthopaedic infections,
including those of bioﬁlm origin, relies on loading poly-
methylmethacrylate (PMMA) bone cement with
antibiotics that elute in vivo [4, 12, 13, 17, 18, 24, 26, 27,
29, 35, 37, 41, 42, 49, 50, 66]. Antibiotic-loaded bone
cements tend to release entrapped pharmaceuticals in a
burst-type fashion and, hence, are effective at delivering
high local levels of an antibacterial agent for a short
postimplantation period, usually a few days [4, 12, 37, 41,
66]. When loaded at high dose, effective antibiotic levels
may be maintained in surrounding tissues for several
months [1, 30, 41]. However, high-dose loading com-
promises mechanical behavior of bone cements [12, 26,
35] likely through direct physical changes in material
architecture related to the addition of nonpolymerizable
species. Antibiotic-loaded PMMA may continue to elute
therapeutic agents for weeks or months at suboptimal
levels. These problems may be partially overcome by
adding water-soluble ﬁllers that increase cement porosity
and facilitate antibiotic release, and vacuum processing
techniques can lead to more homogenous cement com-
positions [9, 43, 46]. Unfortunately, bone cement has a
surface quite suitable for colonization, and although
antibiotic loading can reduce bioﬁlm formation, organisms
are still able to grow, for example, on gentamicin-loaded
bone cements [33, 61].
Additionally, there is much literature dedicated to
polymeric surface modiﬁcation of metal oxides, including
those of titanium, with the goal of blocking protein adhe-
sion and bacterial attachment [15, 22, 28, 40, 54].
Derivatives of poly(ethylene glycol) (PEG) are common in
these antibiofouling and antibioﬁlm strategies [11, 15, 19,
22, 28, 40, 54, 62, 65]. PEG blocks the nonspeciﬁc
adsorption of proteins, cells, and cellular debris through
mechanisms generally attributed to its hydrophilic char-
acter and high surface mobility (steric repulsion) [2, 36,
52]. It is particularly attractive in biomaterial systems
because PEG is nontoxic [2] and well tolerated at high
doses [64]. Polymerizable derivatives of traditional thera-
peutics potentially offer a convenient advantage over other
compounds in that they can be polymerized to implant
materials such as Ti-6Al-4V alloy [38] or copolymerized
with polymeric biomaterials to provide surface-active
antibiotic moieties [39].
We asked whether (1) vancomycin-PEG(3400)-acrylate
[VPA(3400)] polymerized to Ti-6Al-4V alloy reduces
bacterial attachment with respect to PEG controls; (2)
whether the antibioﬁlm effects of VPA(3400) and two
vancomycin-acrylamide derivatives when individually
copolymerized with PMMA bone cement would be statis-
tically superior to vancomycin loading in terms of reduced
adherent bioﬁlm mass; and (3) whether polymerizable
antibiotics when incorporated into PMMA would yield
cement constructs with compressive mechanical properties
similar to PMMA homopolymer and statistically superior
to vancomycin-loaded PMMA.
Materials and Methods
This study involved the synthesis of three polymerizable
vancomycin monomers followed by experimentation along
three lines: (1) coating of Ti alloy with a subset of these
monomers followed by assessment of bacterial surface
attachment; (2) incorporation of monomers into PMMA
bone cement followed by assessment of bioﬁlm prolifera-
tion on composite surfaces; and (3) incorporation of
monomers into PMMA bone cement followed by com-
pressive mechanical testing (Fig. 1).
All monomer synthesis, puriﬁcation, and characteriza-
tion have been described previously [38, 39]. In a slight
modiﬁcation of those procedures, VPA(3400) was puriﬁed
by dialysis only. This modiﬁcation was necessary because
of the large quantities of material required for PMMA bone
cement bioﬁlm experiments. We obtained three polymer-
izable vancomycin derivatives. These compounds are
illustrated (Fig. 2).
The procedure for functionalizing surgical-grade
Ti-6Al-4V alloy bar stock for subsequent polymer attach-
ment has also been described in detail elsewhere [38, 44]
but is illustrated brieﬂy (Fig. 3). To form a comonomer
solution for polymerization to silanized Ti-6Al-4V, 40 mg
VPA(3400) (estimated to be approximately 50% product
with residual PEG[3400]-acrylate and some high-molecu-
lar-weight byproducts) was dissolved in 320 lL Ar-purged
dimethylsulfoxide containing the photoinitiator 2,2-dime-
thoxy-2-phenyl acetophenone at a concentration of 1 mg/
mL along with 80 lL PEG(375)-acrylate. This formulation
results in a calculated PEG(375)-acrylate:VPA(3400) ratio
of approximately 100:1. When nonantibiotic controls were
desired, we omitted the VPA(3400). Surfaces were modi-
ﬁed by photoinitiated polymerization of 15 lLo fa
comonomer solution under 45-mW/cm
2 intensity, colli-
mated, broad-range, ultraviolet light (Hg arc-lamp centered
at 365 nm) for 900 seconds using a Hybralign Series 200
mask alignment system (Oriel Instruments, Stratford, CT)
by techniques detailed elsewhere [31, 38, 56–58]. A 3-day
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123wash protocol [38] was used to elute any detectable
residual monomer, unfunctionalized vancomycin or loosely
entangled polymer chains.
To verify the surfaces were appropriately silanized,
x-ray photoelectron spectroscopy (XPS) was used with a
45 incident monochromatic x-ray beam to characterize
Synthesis of Polymerizable Abx: VPA(3400), VA-1, VA-2
Surface Coating Ti Alloy by Photopolymerization Copolymerization with PMMA Bone Cement
Biofilm Growth  Compressive Mechanical Testing PEG(3000)-Acrl (n = 6)
VPA(3400) (n = 7)
PMMA (n = 11)
Vancomycin 2.5 wt% (n = 3)
Vancomycin 10 wt% (n = 10)
VA-1 10 wt% (n = 5)
VA-2 10 wt% (n = 9)
VPA(3400) 10 wt% (n = 10)
PEG(3000)-acrl 10 wt% (n = 9)
PMMA (n = 5)
Vancomycin 10 wt% (n = 5)
VA-2 10 wt% (n = 3)
VPA(3400) 10 wt% (n = 5)
PEG(3000)-Acrl 5 wt% (n = 5)
PEG(3000)-Acrl 10 wt% (n = 5)
24 hr. Biofilm Growth
￿SEM Quantification of adherent S. epi. 
￿Student t-test
￿Gravimetric Quantification of S. epi. Biofilm
Dry Mass 
￿One-Way ANOVA with Pairwise Comparison
￿Mechanical Testing
￿One-Way ANOVA with 
Pairwise Comparison
Fig. 1 The ﬂow chart illustrates a basic research design having three separate arms of inquiry following chemical synthesis of polymerizable
vancomycin derivatives. The number of samples of each material type examined are shown by ‘‘n’’.
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Fig. 2 Vancomycin was modiﬁed at
the primary amines illustrated. Both
PEG-acrylate and acrylamide polymer-
izable derivatives of vancomycin were
synthesized. The PEG-acrylate deriva-
tive had a 3400 g/mol PEG spacer. For
VA-1 and VA-2, the numeral refers to
the site of modiﬁcation, primary or
secondary amine, respectively. R1 is
classically referred to as the vancomy-
cin V3 position, and R2 is termed the X1
position.
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123oxidized and silanized surfaces; SEM was also used as a
qualitative adjunct to explore the surface features of oxi-
dized surfaces (Fig. 4).
Vancomycin was loaded into ‘‘C*ment 1’’ PMMA
bone cement (Jorgensen Laboratories, Inc, Loveland, CO)
at a concentration of 1 g vancomycin to 40 g bone
cement powder (2.5 wt%, a standard, prophylactic loading
dose) or at a concentration of 4 g to 40 g bone cement
powder (10 wt%, a high, therapeutic loading dose).
VPA(3400), VA-1, VA-2, and PEG(3000)-acrylate were
loaded at 10 wt%. Cylinders were constructed by ﬁrst
dissolving the desired additive in water and mixing with
bone cement powder to create a slurry. The slurry was
then ﬂash-frozen using liquid nitrogen and lyophilized to
recover a homogeneous powder. Bone cement cylinders
were polymerized by addition of monomer liquid
according to the manufacturer’s directions. Cylinders of
dimensions 10 mm 9 5 mm (height 9 diameter) were
formed using a Teﬂon mold.
Substrates (polymer-coated Ti alloy) were placed in
50 mL brain heart infusion (BHI) medium, and the medium
was inoculated with Staphylococcus epidermidis ATCC
35984 (clinical, bioﬁlm-forming isolate). BHI medium was
used in previous studies of polymerizable vancomycin
derivatives [38, 39] and, for consistency, was used here.
Samples were incubated on a rotary shaker at 100 rpm at
37C. Polymer-coated Ti samples were allowed to incubate
for 24 or 72 hours. Twenty-four-hour samples were
removed, rinsed with copious amounts of water to wash
away unbound organisms, and prepared for SEM. Seventy-
two-hour specimens were inspected visually. The SEM
preparatory procedure consisted of 1-hour ﬁxation in 10%
(v/v) phosphate-buffered formalin (Fisher Scientiﬁc, Kal-
amazoo, MI) followed by an ethanol dehydration series: 15
minutes in 50:50 ethanol:H2O, 15 minutes in 75:25 etha-
nol:H2O, 15 minutes in 95:5 ethanol:H2O, and 30 minutes
in 100% ethanol. The samples were then placed in hex-
amethyldisilazane (Electron Microscopy Sciences,
Hatﬁeld, PA) for 1 hour 45 minutes, removed, frozen,
lyophilized, and gold-coated. SEM images were obtained
at 750x magniﬁcation using a JSM-6480LV system (JOEL
Ltd, Tokyo, Japan). A minimum of 10 random images was
taken of each sample coupon by panning the microscope to
non-predetermined regions about the test coupon and then
quantifying adherent organisms. Organisms were not visi-
ble during the panning procedure, only when the
microscope came to a complete stop. Adherent Staphylo-
coccal organisms were counted, and an average surface
density was calculated for each coupon using area mea-
surements from ImageJ Version 1.33u software (National
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Fig. 3A–D A schematic of the Ti surface modiﬁcation procedure is
shown. (A) The native oxide surface is represented. (B) The native
oxide surface is thickened and the number of surface hydroxyl groups
are presumably increased. (C) Surface hydroxyls are reacted with
methacryloxypropyltrimethoxysilane in anhydrous toluene. This
reaction effectively places a layer of methacrylate groups on the
surface that can participate in free radical polymerization and anchor
polymer chains to the surface. (D) Covering the methacrylated surface
with a monomer solution containing a polymerizable antibiotic
(VPA[3400] in this case), another polymerizable species (PEG[375]-
acrylate), and a photoinitiator followed by exposure to ultraviolet
radiation results in polymerization. A fraction of the polymer chains
are covalently attached to the surface, albeit in a geometrically more
complex structure than that shown here. In this reaction scheme, a
polyacrylate backbone is formed with pendant VPA(3400) and
PEG(375). Here, assuming ideal polymerization, n = 9 and n = 80.
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123Institutes of Health, Bethesda, MD). This approach was
repeated for each Ti sample of varying surface type.
PMMA cylinders were incubated analogously except
they were transferred to fresh media every 22 hours.
Twenty-two hours was chosen as a time point for media
collection as this marked the onset of bacterial suspension
turbidity, and there was concern for inappropriate bacterial
death with incubation under turbid conditions. At 22, 44,
66, and 88 hours, cylinders were collected, freeze-dried
before adherent bioﬁlm mass was determined gravimetri-
cally (bioﬁlm dry weight) to the closest 1/10 milligram
using a standard analytical balance and a modiﬁcation of
methods described elsewhere [59]. We used 4-day growth
data for comparing surface types. Vancomycin-loaded
cylinders released active antibiotic for the ﬁrst 22 hours at
levels sufﬁcient to inhibit bacterial growth in the incuba-
tion vessel as these vancomycin-containing vessels did not
go on to reach turbidity if allowed to incubate further.
However, if fresh media were supplied, bacterial growth
commenced over subsequent time intervals. Accordingly,
for vancomycin-loaded samples, reported time points were
adjusted by subtracting 22 hours and represent hours after
observed burst elution.
PMMA and PMMA-composite compressive mechanical
properties were measured using an MTS 858 MiniBionix II
system (MTS Systems Corp, Eden Prairie, MN) with a
platen speed of 1 mm/min. Stress strain data were analyzed
external to the system software. Compressive modulus was
calculated as the slope of the elastic deformation region
using a standard linear least squares ﬁt. Yield strength
(stress at the transition between elastic and plastic defor-
mation) was calculated using a 0.002 offset method.
Resilience was calculated as the area under the stress-strain
curve up to yield strength. Fracture strength, when appli-
cable, was taken as the stress at catastrophic failure.
We determined by SEM differences in the average
number of adherent S. epidermidis organisms between Ti
alloy surfaces coated with PEG(375)-acrl (n = 6) and
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Fig. 4A–E Scanning electron microscopy (91000) provides a qual-
itative means of visualizing changes in Ti-6Al-4V surface structure
(A) before and (B) after oxidation with H2SO4:H2O2 solution. This
oxidation procedure serves to increase the number of surface hydroxyl
groups available for subsequent functionalization with a silane
reagent. XPS allows for elemental characterization of Ti-6Al-4V
surfaces having undergone modiﬁcation as described in Fig. 3. The
number of electrons ejected per second is plotted against electron
binding energy. (C) The native oxide is shown. Oxygen and titanium
are the primary elements present, but some level of N, C, Na, and Cl
contamination exists as well. Residual Ar is present from the XPS
surface preparation procedure. (D) The oxidation process increased
the oxide content of the surface and possibly changed the structure of
the Ti 2p peak. These ﬁndings are consistent with oxide replacement
of Ti-6Al-4V in the surface layer. (E) Silanization leads to a further
attenuated Ti 2p peak, an increased C 1 s peak, and the appearance of
Si 2 s and Si 2p peaks. This collection of observations is consistent
with the formation of a siloxane layer over the Ti-6Al-4V oxidized
surface.
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123VPA(3400)-PEG(375)-acrl (n = 7) using the Student’s
t-test. We determined differences in adherent bioﬁlm dry
mass between PMMA cylinders (n = 11), PMMA cylin-
ders incorporating vancomycin at 2.5 wt% (n = 3),
vancomycin at 10 wt% (n = 10), VPA(3400) at 10 wt%
(n = 10), VA-1 at 10 wt% (n = 5), VA-2 at 10 wt%
(n = 9), or PEG(3000)-acrylate at 10 wt% (n = 9) using
the one-way analysis of variance (ANOVA) in combination
with the Tukey Test for pairwise comparisons. We deter-
mined differences in compressive modulus, yield strength,
resilience, fracture strength, and strain at fracture between
PMMA coupons (n = 5), PMMA coupons incorporating
vancomycin 10 wt% (n = 5), VPA(3400) 10 wt% (n = 5),
PEG(3000)-Acrl 5 wt% (n = 5), PEG(3000)-Acrl 10 wt%
(n = 5), and VA-2 10 wt% (n = 3) using the one-way
ANOVA in combination with the Tukey test for pairwise
comparisons. Levine’s test was used to check the
assumption of equal sample variances, and the
Kolmogorov-Smirnov test along with visual examination
of normal probability plots was used to verify data nor-
mality for all ANOVA analyses.
Results
In the 24-hour growth experiment to assess the initial
attachment of organisms to the polymer-coated Ti alloy
surfaces the SEM observations followed by quantiﬁcation
of adherent organisms suggested the VPA(3400) copoly-
mer reduced (p = 0.007) the number of organisms by
approximately fourfold relative to the PEG(375)-acrylate
surface (Fig. 5). The bare oxide surface was covered with a
conﬂuent layer of organisms, making enumeration
impractical. In a separate 72-hour growth experiment with
oxidized Ti-6Al-4V alloy, PEG(375)-acrylate coated alloy,
and VPA(3400)-PEG(375)-acrylate coated alloy, the bare
5 µm
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Fig. 5A–E (A) Three Ti alloy discs exposed to bioﬁlm-forming
Staphylococcus epidermidis culture for 66 hrs are shown. The
composition of the surface coatings (top surface only) are illustrated
(arrows). (B) The same three discs are shown from a second
perspective. Bare oxide surface is completely covered with bioﬁlm.
The coated portion of the PEG(375)-acrylate disc is visually clean.
The coated portion of the VPA(3400)-PEG(375)-acrylate disc is
visually clean as well. These ﬁgures clearly demonstrate the
antibioﬁlm properties of PEG-type coatings. (C) A scanning
electron microscopy (SEM) image of S. epidermidis bioﬁlm at
95000 magniﬁcation is shown (66 hours in culture). Cocci are
apparent as is glycocalyx. (D) An SEM image at 9750 magniﬁ-
cation shows attachment of S. epidermidis on PEG(375)-acrylate-
coated Ti alloy (24 hours in culture). Images of this sort (without
obscuring glycocalyx) were used to quantify attached organisms on
both PEG and VPA(3400) surfaces. The white spots are bacteria.
(E) Both surfaces reduced the number of attached organisms.
However, data suggest that having VPA(3400) in the copolymer
reduces bacterial attachment more effectively than PEG(375)-
acrylate alone.
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123oxide surface was completely covered with bioﬁlm
organisms and glycocalyx (Fig. 5A–B). Both polymer-
coated surfaces were visually clear of bacteria.
In separate experiments with PMMA-antibiotic com-
posites, after 4 days under growth conditions, the mass of
adherent organisms and glycocalyx was reduced on 10 wt%
VPA(3400)-PMMA and 10 wt% PEG(3000)-acrylate-
PMMA relative to PMMA controls (p\0.01 for both
comparisons). Ten wt% VA-1 and VA-2 composites were
associated with a similar mass of adherent organisms and
glycocalyx on PMMA. Bacteria colonized and grew on
high-dose vancomycin-loaded PMMA (10 wt% vancomy-
cin), and bioﬁlm mass showed an exponential increase with
time (Fig. 6A). Low-dose or high-dose loading of
vancomycin did not reduce bioﬁlm mass. However, both 10
wt% VPA(3400)-PMMA and 10 wt% PEG(3000)-acrylate-
PMMA had less bioﬁlm than high-dose vancomycin
cement (p = 0.08 and p = 0.09, respectively) (Fig. 6B).
We observed adverse mechanical effects of adding
vancomycin to PMMA bone cement and also the potential
mechanical property advantages of adding a polymerizable
antibiotic derivative to PMMA (Table 1; Fig. 7A). Van-
comycin loaded at 10 wt% in PMMA bone cement
decreased the compressive modulus by 20% (p = 0.01),
yield strength by 16% (p\0.0001), resilience by 17%
(p = 0.02), fracture strength by 41% (p\0.0001), and
strain at fracture by 35% (p = 0.02). Conversely, VA-2 did
not decrease any mechanical property and rather increased
(p = 0.1) the compressive modulus 13% with respect to
PMMA. Relative to PMMA, VPA(3400) decreased the
compressive modulus by 36% (p\0.001), yield strength
by 38% (p\0.001), and resilience by 43% (p\0.001).
Relative to PMMA, PEG(3000)-acrylate incorporated at 10
wt% decreased the same mechanical properties to a similar
degree (Table 1).
Discussion
Bioﬁlm-forming organisms continue to be a central concern
in orthopaedic procedures which involve the placement of
metallic hardware in conjunction with PMMA bone cement.
We present initial work to evaluate the usefulness of van-
comycin-PEG-acrylate and vancomycin-acrylamide species
for the inhibition of S. epidermidis bioﬁlm formation on
both Ti-6Al-4V orthopaedic alloy and on PMMA bone
cement.. We evaluated: (1) whether VPA(3400) polymer-
ized to Ti-6Al-4V alloy reduces bacterial attachment; (2)
the antibioﬁlm effects (reduced bioﬁlm mass) of
VPA(3400) and two vancomycin-acrylamide derivatives
when individually copolymerized with PMMA bone
cement; and (3) the compressive mechanical effects of
adding polymerizable antibiotics to PMMA bone cement.
We acknowledge limitations to our experiment. First is
that the bioﬁlm growth conditions presented may not
reﬂect those encountered in vivo. A bioﬁlm bioreactor
might offer a more sophisticated approach to simulating
growth conditions [3, 10, 34]. However, it is inherently
difﬁcult to deﬁne the complex milieu of an infection site,
and the assays used here were sufﬁcient to deﬁne differ-
ences between material types. Second, the traditional
method of quantifying adherent bioﬁlm is by measurement
of viability by prior desorption (ultrasonication) and sub-
sequent agar plating [25], though there is often
considerable variability in the absolute bacterial count
obtained by different methods [48]. Quantiﬁcation by SEM
is often limited [25] secondary to problems of bacterial
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Fig. 6A–B (A) Staphylococcus epidermidis bioﬁlms readily prolif-
erate on PMMA bone cement and vancomycin-loaded PMMA bone
cement. Even high-dose vancomycin loading does not prevent bioﬁlm
formation after initial burst release, although it tends to increase
experimental variability. This outcome may be related to inconsistent
elution of small amounts of entrapped antibiotic. (B) Various species
were added to PMMA bone cement to evaluate antibioﬁlm activity.
Eighty-eight-hour time points are shown. Neither of the vancomycin-
acrylamides were effective. Both VPA(3400) and PEG(3000)-acrylate
reduced adherent organisms with respect to PMMA. These observa-
tions suggest ethylene glycol functionalities are largely responsible
for the observed antibioﬁlm properties in this assay.
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123enumeration arising from bacterial agglomerates and
matrix-embedded bacteria [25, 55, 60] and from the pos-
sibility that some of the bioﬁlm structure will be lost during
preparation [23, 63]. For this reason, our SEM quantiﬁca-
tion methods were limited to measurement of initial
bacterial attachment where extensive glycocalyx was not
present and where relative bacterial surface density was
low. We expect the reported bacterial surface densities
(Fig. 5) to be technique dependent as with other methods
[48]. Dry mass has also been used to quantify bioﬁlm
proliferation [51, 59]; however, the gravimetric assay used
here to evaluate adherent bioﬁlm mass on PMMA surfaces
does not provide adequate precision for discriminating
between the effects of VPA(3400) and PEG(3000)-acry-
late. Third, although we demonstrated various statistically
signiﬁcant effects attributable to polymerizable antibiotic
species, whether these effects will have clinical importance
is a question for future work.
In experiments with polymer-coated Ti alloy,
VPA(3400) appears to add an additional level of protection
to PEG-type coatings (Fig. 5). Surface-contact killing may
contribute to the decreased number of adherent bacteria
during the initial stages of biomaterial colonization. It is
likely this period is critical in true physiological infections
in which the bacterial load in the surrounding ﬂuids is
generally expected to be low. In comparison, a recently
described antimicrobial technique involves the covalent
attachment of an antibiotic (presumably a monolayer) to
titanium [5–7, 21, 32, 47]. Building on surface modiﬁca-
tion methods described by Nanci et al. [44], the authors
were able to attach vancomycin to titanium via two am-
inoethoxyethoxyacetate linkers. One study suggested
Staphylococcus aureus attachment may be blocked using
this surface-modiﬁcation platform [7]. However, because
aminoethoxyethoxyacetate linkers (sold commercially as
‘‘Mini-PEG’’) effectively put a thin PEG layer on a surface
(four ethylene glycol units), some of the observed anti-
bioﬁlm properties may be related to the linker chemistry.
Another study reported as few as four ethylene glycol
repeats can provide antibiofouling properties for 3 weeks
or longer with some cell types [22].
The data show incorporation of PEG moieties into the
PMMA architecture retards but ultimately does not prevent
bioﬁlm adherence. This effect may be related to blockage
of initial bacterial attachment, as suggested in other studies
with PMMA [16, 53], but may be overcome as the surface
is saturated with bacterial glycocalyx and cellular debris.
Table 1. Compressive mechanical properties for PMMA bone cement with various additives are shown. VA-2 composite properties are very
similar to those of PMMA. Species with PEG functionalities lead to mechanical property compromise
Material Compressive
modulus (MPa)
Yield strength
(MPa)
Resilience (J/cm
3) Fracture
strength (MPa)
Strain at
fracture (%)
PMMA 25 ± 1 (100%) 85 ± 3 (100%) 3.0 ± 0.2 (100%) 96 ± 13 (100%) 31 ± 7 (100%)
Vancomycin 10wt% 20 ± 1 (80%) 71 ± 2 (84%) 2.5 ± 0.3 (83%) 57 ± 5 (59%) 20 ± 3 (65%)
VA-2 10wt% 28.2 ± 0.4 (113%) 87 ± 1 (102%) 2.8 ± 0.3 (93%) 90 ± 2 (94%) 31 ± 3 (100%)
VPA(3400) 10wt% 16 ± 3 (64%) 53 ± 2 (62%) 1.7 ± 0.2 (57%) 76 ± 8 (79%)* 34 ± 2 (110%)*
PEG(3000)-Acrl 5wt% 20.7 ± 0.5 (83%) 59 ± 2 (69%) 1.9 ± 0.1 (63%) 72 ± 6 (75%)* 33 ± 3 (106%)*
PEG(3000)-Acrl 10wt% 15 ± 1 (60%) 44 ± 4 (52%) 1.4 ± 0.2 (47%) 50 ± 7 (52%)* 27 ± 6 (87%)*
Asterisks indicate materials with potential microcracking.
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Fig. 7A–B (A) Representative stress-strain curves are shown for
PMMA bone cement with various additives (compressive tests).
Loading vancomycin-acrylamide-2 (VA-2) at 10 wt% results in
properties similar to those of PMMA, suggesting that polymerizable
antibiotic derivatives may avoid some of the problems classically
encountered with high-dose vancomycin loading. However, adding
VPA(3400) at 10 wt% severely compromises mechanical properties
and may lead to microcracking. This behavior is likely the result of
the bulky PEG linker or its hydrophilicity. It is expected that an
optimum number of ethylene glycol repeats would result in properties
between those of VA-2 and VPA(3400) while at the same time offer
antibioﬁlm properties. (B) Key mechanical properties are illustrated.
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123Neither of the vancomycin-acrylamide derivatives showed
an antibioﬁlm effect. This behavior is consistent with
previous observations [39] suggesting the PEG linker is
critical for antibacterial activity once vancomycin deriva-
tives are polymerized from solid substrates. In an
alternative approach, a quaternary amine dimethacrylate
(QADMA) species was copolymerized with PMMA bone
cement, and antibioﬁlm properties against Escherichia coli
were examined [16, 53], but no quantiﬁcation of adherent
organisms was undertaken. Data suggested QADMA
blocked the attachment of Escherichia coli; whether this
was related to the killing of microorganisms is less clear.
Mechanical testing of antibiotic-loaded bone cements
(Table 1) conﬁrms that adding vancomycin at 10 wt%
decreases compressive modulus, yield strength, resilience,
and fracture strength, which is consistent with previous
reports [12, 26, 35]; for example, Klekamp et al. [35]
showed that, in fatigue tests, loading vancomycin at 7.5
wt% decreased the number of cycles to failure by 50%.
Substituting the acrylamide-modiﬁed vancomycin deriva-
tive VA-2 at 10 wt% restores all measured mechanical
deﬁcits and may actually increase the compressive modu-
lus. These improvements likely occur because the
acrylamide functionality copolymerizes with methacrylate
groups during bone cement curing, whereas vancomycin
does not. Conversely, vancomycin may leave gross struc-
tural cavities in the cement or act as a plasticizer.
Unfortunately, VA-2 and VA-1 were not effective at
blocking bioﬁlm formation in the assay presented here,
suggesting it was the PEG functionality that conferred
antibioﬁlm properties and also mechanically compromised
the cements. PEG is known to confer resistance to cellular
or protein attachment [19, 22, 65], and the PEG tether is
reportedly important for increasing surface-based activity
of VPA-type species [39]. There may be some optimal
number of ethylene glycol units that confers adequate
antibacterial activity without sacriﬁcing bone cement
mechanical integrity.
Data with coated Ti alloy surfaces suggest copolymer-
izing a PEGylated vancomycin species, VPA(3400), with
PEG(375)-acrylate is more effective than PEG alone at
blocking S. epidermidis bioﬁlms. The PEG spacer itself
likely contributes to the antibioﬁlm effect, but SEM data
indicate the pendant vancomycin molecule improves the
antimicrobial effect under some growth conditions. Load-
ing PMMA bone cement with certain polymerizable
vancomycin derivatives may eventually be useful for
retarding bioﬁlm adherence without compromising
mechanical properties, although the current formulations
did one or the other, but not both. A vancomycin-acryl-
amide additive resulted in compressive mechanical
properties almost identical to PMMA controls but did not
inhibit bioﬁlm growth. VPA(3400) reduced bioﬁlm growth
but compromised mechanical properties. Experiments de-
scribed here should facilitate the development of new
antibioﬁlm biomaterial surfaces.
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